Mark Schoenebaum has joined Inc. as a managing director and senior research analyst in Equity Company Research within the Global Markets division.
Schoenebaum is based in New York and reports to Steve Pollard, managing director and Americas head of research.
Schoenebaum joins Deutsche Bank from Bear Stearns, where he was a senior managing director covering Biotechnology in equity research. He has spent the past eight years as an equity research analyst, the last three of which he was ranked #1 in the Institutional Investor All-America Research poll for Biotechnology.
Before joining Bear Stearns, Schoenebaum was co-director of Healthcare equity research at Alexandra Investment Management and spent two years as an analyst at Piper Jaffray. Schoenebaum earned a B.A. from Indiana University and an M.D. from Johns Hopkins University School of Medicine.
In addition, Robyn Karnauskas has joined as a vice president and research analyst in Equity Company Research. Karnauskas was previously an associate director at Bear Stearns covering Biotechnology. She is based in New York and reports to Schoenebaum. Karnauskas earned a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Cancer Biology from the University of Chicago.
“We are thrilled to add Mark and Robyn to our Healthcare team to cover Biotechnology. We are confident that their scientific knowledge and financial services experience will enhance the suite of objective, thematic and actionable ideas we regularly provide to our clients,” says Pollard.